CompanyGraph
Kingchem Liaoning Life Science Co., Ltd.
301509 · SZSE · China
kingchemchina.comFinancials as of FY2025
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
2.92%
Annual Rate
CNY 0.90Paid annual
Payout Ratio
173.1%High
Payback Period
34.7 yr
Last Ex-Dividend
Jun 2, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.60BCNY536.68M · vs all stocks (USD)
Trailing P/E
57.42xRevenue (TTM)
600.30MCNY89.58M · vs all stocks (USD)
Profit Margin
10.55%Beta
0.3260xvs all stocks
52-Week Change
-15.68%vs all stocks
Market Capitalization
3.60BCNY536.68M · vs all stocks (USD)
Enterprise Value
2.20BCNY328.63M · vs all stocks (USD)
Trailing P/E
57.42xPrice to Sales (TTM)
5.99xPrice to Book (MRQ)
1.69xEnterprise to Revenue
3.67xEnterprise to EBITDA
18.78xGross Margin
35.22%Profit Margin
10.55%Operating Margin
7.63%Return on Assets (TTM)
1.59%Return on Equity (TTM)
2.94%Revenue (TTM)
600.30MCNY89.58M · vs all stocks (USD)
Revenue per Share (TTM)
4.95CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-6.30%Gross Profit (TTM)
222.04MCNY33.13M · vs all stocks (USD)
EBITDA (TTM)
78.46MCNY11.71M · vs all stocks (USD)
Net Income (TTM)
63.32MCNY9.45M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-44.00%Operating Cash Flow (TTM)
140.02MCNY20.89M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
50.26MCNY7.50M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.9000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
2.92%vs all stocks
Payout Ratio
173.08%Revenue
639.37MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
367.70MCNYFY2025 · Dec 31, 2025Gross Profit
271.67MCNYFY2025 · Dec 31, 2025Operating Income
113.51MCNY16.94M · vs all stocks (USD)
Pre-tax Income
120.92MCNYFY2025 · Dec 31, 2025Income Tax Expense
16.11MCNYFY2025 · Dec 31, 2025Net Income
104.81MCNYFY2025 · Dec 31, 2025EBIT
121.11MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
198.38MCNYFY2025 · Dec 31, 2025Research & Development
35.91MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
34.09MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.31MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.06MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
193.02KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.8700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.8700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
120.47MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
120.47MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
104.81MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-80.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
-122.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
370.74MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
104.81MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.43MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-237.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
44.56MCNYFY2025 · Dec 31, 2025Capital Expenditures
-41.81MCNYFY2025 · Dec 31, 2025Sale of Investments
20.41MCNYFY2025 · Dec 31, 2025Other Investing Activity
85.79MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
64.39MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-48.37MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.93MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-50.30MCNYFY2025 · Dec 31, 2025Shares Outstanding
120.45MSharesUpdated Sep 21, 2026Float Shares
56.74MSharesUpdated Sep 21, 2026% Held by Insiders
57.75%vs all stocks
% Held by Institutions
5.20%vs all stocks
Total Cash (MRQ)
1.40BCNY208.40M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.60CNYUpdated Sep 21, 2026Total Debt (MRQ)
2.36MCNY352.17K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0011xCurrent Ratio (MRQ)
13.39xBook Value per Share (MRQ)
17.66CNYUpdated Sep 21, 2026Total Assets
2.32BCNY346.15M · vs all stocks (USD)
Total Current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Liabilities
112.70MCNYFY2025 · Dec 31, 2025Total Non-current Assets
708.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
19.37MCNYFY2025 · Dec 31, 2025Total Current Liabilities
93.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
370.74MCNYFY2025 · Dec 31, 2025Other Short-term Investments
713.06MCNYFY2025 · Dec 31, 2025Accounts Receivable
106.13MCNYFY2025 · Dec 31, 2025Inventory
144.68MCNYFY2025 · Dec 31, 2025Accounts Payable
42.53MCNYFY2025 · Dec 31, 2025Short-term Debt
1.40MCNYFY2025 · Dec 31, 2025Other Current Liabilities
859.00CNYFY2025 · Dec 31, 2025Long-term Debt
1.82MCNYFY2025 · Dec 31, 2025Common Stock (Book)
120.45MCNYFY2025 · Dec 31, 2025Retained Earnings
417.52MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.21BCNY329.34M · vs all stocks (USD)
52-Week Low
25.65CNYUpdated Sep 21, 202652-Week High
48.60CNYUpdated Sep 21, 202652-Week Change
-15.68%vs all stocks
Beta
0.3260xvs all stocks
50-Day MA
29.57CNYUpdated Sep 21, 2026200-Day MA
34.10CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.90MSharesUpdated Sep 21, 2026Avg 30-Day Volume
4.26MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.5200CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.73Dividend per Share: 0.90Earnings per Share: 0.52
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule